Navigation Links
ExoSeal vascular plug gets good reviews in ECLIPSE study
Date:4/1/2008

CHICAGO, Ill. (April 1, 2008) A new bioabsorbable plug that seals the arterial puncture site used for threading catheters into the body during diagnostic angiography and interventional procedures significantly shortens bleeding time and enables patients to get up and walk around far sooner than when manual compression is applied to the groin. In addition, there were no access site complications at 30 days in the ECLIPSE Trial, a multicenter randomized study that is testing the safety and effectiveness of the investigational ExoSeal vascular closure device.

The study will be reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

We demonstrated that the ExoSeal device is a great alternative to manual compression following diagnostic and interventional procedures, said Shing-Chiu Wong, MD, a professor of medicine at Weill Medical College of Cornell University and director of the cardiac catheterization laboratories at New York Presbyterian Hospital/Weill Cornell Medical Center, New York City. It enables early ambulation and, potentially, early discharge from the hospital following the procedure.

The ExoSeal Vascular Closure Device consists of a felt-like plug made of polyglycolic acid. It is anchored in place on top of the puncture in the femoral artery, after the catheter is removed. Because none of the plug is inserted into the artery itself, it does not interfere with blood flow. Over about three months, it completely dissolves. By comparison, manual compression involves exerting pressure on the femoral artery by hand or through use of a weight or clamp. This process can be uncomfortable for patients. It can take up to roughly 20 minutes for the bleeding to stop and several hours before the patient can get up from lying flat in bed.

For the study, Dr. Wong and his colleagues recruited 488 patients from 17 medical centers, half of whom were undergoing diagnostic angiography and half, an interventional procedure. Some 90 percent were being examined or treated for coronary disease, the remaining 10 percent for peripheral disease. Patients were randomly assigned to treatment with the ExoSeal or to manual compression.

The ExoSeal device was put into place in an average of just one minute and was used successfully in 89.1 percent of patients. There was no difference in procedural success between the ExoSeal and manual compression groups (91.8 percent and 91.0 percent, respectively). However, the average time to cessation of bleeding was significantly shorter in patients treated with the ExoSeal (4.38 minutes vs. 20.05 minutes, p<0.0001). Similarly, patients treated with the vascular closure device were able to get out of bed and walk around far sooner, within 2.54 hours, on average, with the ExoSeal, as compared with 6.24 hours with manual compression (p=0.028).

The next research step will be to put the ExoSeal to tougher challenges. Further investigation is needed to delineate the devices applicability in patients with access puncture sites at or below the branchpoint of the femoral and iliac arteries and in patients with mild or moderate peripheral vascular disease, he said. Comparative studies of efficacy and patient comfort with the ExoSeal and other vascular closure devices will also be intriguing.

Dr. Wong will present the results of the "Ensures Vascular Closure Device Speeds Hemostasis (ECLIPSE) study on Tuesday, April 1 at 11:00 a.m. CDT in the Grand Ballroom, S100.


'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. 2-drug blood pressure therapy lowers cardiovascular risk
2. Decreased sexual satisfaction is not associated with cardiovascular disease in postmenopausal women
3. Mary Matalin and John Ray Join the Cheney Cardiovascular Institute Board of Directors
4. Eric J. Topol, M.D., to Present Late-Breaking Lecture About Advancements in Genomics of Cardiovascular Disease at ACCs 57th Annual Scientific Session
5. Medical Simulation Corporation to Present Comprehensive Cardiac Patient Scenario at the Society for Cardiovascular Angiography and Interventions (SCAI) and American College of Cardiology (ACC) Conference
6. Study finds certain liver disease related to cardiovascular fitness
7. Randy Jackson and the American Heart Association Educate Raleigh Area Residents About the Connection Between Type 2 Diabetes and Cardiovascular Disease
8. Cardiovascular nursing: Striving for excellence in the care of cardiac patients
9. Glaucoma May Boost Cardiovascular Death Risk in Blacks
10. Mayo Clinic proceedings highlights research about cardiovascular benefits of omega-3 fatty acids
11. LeMaitre Vascular Reports Q4 2007 Revenue of $11.1 Million, a 27% Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 2017 , ... The Bryant Agency, a Georgia based firm ... in the Dalton region, is working in conjunction with the GreenHouse organization in ... abuse. , The GreenHouse is headquartered in Dalton and provides a refuge for ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... assistance and financial planning services to communities in the greater Birmingham area, is ... provide resources to underprivileged young people in the region. , The Chris Hammond ...
(Date:7/21/2017)... ... , ... Hospital M&A activity slowed in the second quarter of 2017, according ... to 23 in the second quarter, up 15% from the 20 publicly announced acquisitions ... in the year-ago second quarter. Only four of the transactions disclosed a purchase price ...
(Date:7/21/2017)... ... July 21, 2017 , ... The ... grant from the C. R. Bard Foundation, Inc. to support the ... , a service available through the nonprofit home care agency. Using evidence-based methods, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to announce the ... July 17, 2017, Ms. Vu will join West Dermatology’s large network of medical and ... skin cancer , and more. She graduated from the University of Florida College ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... CARLSBAD, Calif. , July 10, 2017  The ... in Boston, MA at the ... unequaled value and unparalleled access to global decision makers ... to draw 800+ life science leaders during two impactful ... Boston, and provides delegates with additional networking opportunities with ...
(Date:7/5/2017)... JERUSALEM , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company ... today that it has received approval from the Israel Securities ... Stock Exchange (TASE). Oramed common stock will commence trading on ... Based on the current market capitalization of the Company, it ...
Breaking Medicine Technology: